Research Article| Volume 38, ISSUE 4, P453-463, October 1988

Download started.


The effects of norplante-2 rods on clinical chemistry in Singaporean acceptors after 1 year of use: Metabolic changes

      This paper is only available as a PDF. To read, Please Download here.


      In this longitudinal study involving 100 Singaporean acceptors, the effects of Norplant®-2 rods on metabolic function was evaluated. With respect to liver function, the results indicate possible hepatocellular dysfunction. There was a significant rise in mean serum bilirubin from 0.54 mg/dl to 0.85 mg/dl after 12 months of use (p < 0.001). Furthermore, there was also a significant fall in total proteins from 7.37 gm/dl to 7.12 gm/dl (p < 0.001) and serum globulin from 3.18 gm/dl to 2.84 gm/dl (p < 0.001).
      As regards lipid metabolism, we have demonstrated significant decreases in mean serum triglycerides (1.04 mmol/l to 0.83 mmol/l), p < 0.001; total cholesterol (5.04 mmol/l to 4.64 mmol/l), p < 0.001; and LDL-cholesterol (3.36 mmol/l to 3.10 mmol/l), p < 0.001 after one year of use. There was a small fall in the HDL-cholesterol (1.21 mmol/l to 1.16 mmol/l) after 12 months of use; this fall was not significant. Despite this, there was a rise in the HDL-cholesterol/Total cholesterol -HDL-cholesterol ratio (0.258 cf 0.244; p < 0.05) after 1 year of use. As we have not incorporated a simultaneous non-pill treated control group, the observed changes in lipoprotein lipids could be attributed to extraneous factors such as diet, exercise or other environmental changes. Nevertheless, the findings, though speculative, indicate Norplant®-2 use to be non-contributory to cardiovascular risk and indeed it may be a protective factor against such risks in this population. The use of Norplant®-2 rods was not associated with any significant effect on glucose tolerance after 12 months of use.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Contraception
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Kay CR
        The Royal College of General Practitioners. Oral Contraception Study.
        Obstet Gynecol. 1964; 11: 759-786
        • Vessey MP
        Female Hormone and Vascular Complications.
        J Fam Plann Suppl. 1980; 6: 1-12
        • Asted B
        Oral Contraceptive and Some Debatable Side Effects.
        Acta Obstet Gynecol Scand Suppl. 1982; 105: 17-23
        • Stadel BV
        Oral Contraceptive and Cardiovascular Disease.
        New Engl J Med. 1981; 305: 612-618
        • Gordon T
        • Castelli WP
        • Hjortland MC
        • Kannel WB
        • Deuwher TR
        High Density Lipoprotein as a Protective Factor against Coronary Heart Disease.
        Am J Med. 1977; 62: 707-714
        • Castelli WP
        • Doyle JI
        • Gordon T
        • Hames CG
        • Hjortland ML
        • Hulley SB
        • Kagan A
        • Zukel J
        HDL Cholesterol and Other Lipids in Coronary Disease.
        Circulation. 1977; 55: 767-772
        • Bradely DD
        • Wingred J
        • Pelitti DB
        • Krauss RM
        • Ramachandran S
        Serum High Density Lipoprotein Cholesterol in Women using Oral Contraceptive, Oestrogens and Progestins.
        New Engl J Med. 1978; 299: 17-20
        • Kay RC
        Progestogens and Arterial Disease: Evidence from the Royal College of General Practitioners' Study.
        Am J Obstet Gynecol. 1982; 142: 762-765
        • Wingrave SJ
        Progestogen Effects and their Relationship to Lipoprotein Changes.
        Acta Obstet Gynecol Scand Suppl. 1982; 105: 33-36
        • Cramp DG
        New Automated Method for Measuring Glucose by Glucose Oxidase.
        J Clin Pathol. 1967; 20: 910-912
        • Weichselbaum TE
        An Accurate and Rapid Method for the Determination of Proteins in Small Amounts of Blood Serum and Plasma.
        Am J Clin Pathol. 1946; 16: 40-49
        • S̀pencer K
        • Price CP
        Influence of Reagent Quality and Reaction Conditions on the Determination of Serum Albumin by the Bromocresol Green-dye Binding Method.
        Ann Clin Biochem. 1977; 14: 105-115
        • Jendrassik L
        • Grof P
        Simplified Photometric Methods for the Determination of the Blood Bilirubin.
        Biochemische Zeitschrift. 1938; 297: 81-89
        • Bessey OA
        • Lowry OH
        • Brock MJ
        A Method for the Rapid Determination of Alkaline Phosphatase with Five cubic millimetres of Serum.
        J Biol Chem. 1946; 164: 321-329
        • Burstein M
        • Scholnick HR
        • Morfin R
        Rapid Method for the Isolation of Lipoproteins from Human Serum by Precipitation with Polyanions.
        J Lipid Res. 1970; 11: 583-595
        • Stahler F
        • Gruber W
        • Stinohoff K
        • et al.
        Eine praxisgerechte enzymatic Cholesterin-Bestimmung.
        Med Lab (Stuttg). 1977; 30: 29-37
        • Trinder P
        Determination of Glucose in Blood using Glucose Oxidase with an Alternative Oxygen Acceptor.
        Ann Clin Biochem. 1969; 6: 24-27
        • Wahfield AW
        2nd English Ed. Methods of Enzymatic Analysis. 4 vols. Verlag Chemie Weinheim and Academic Press, New York and London1974: 1831
        • Friedewald WI
        • Levy RI
        • Fredrickson DS
        Management of Hyperlipidaemia.
        Clin Chem. 1982; 18: 499-502
        • World Health Organisation
        Facts about an Implantable Contraceptive.
        Bulletin of the World Health Organisation. 1985; 63: 485-494
        • Pasquale SA
        • Brandel S
        • Cruz RI
        • Kelly S
        • Sweeney M
        Norplant® Contraceptive Implants - Rods versus Capsules.
        Contraception. 1987; 36: 305-316
        • Croxatto HB
        • Diaz S
        • Robertson DN
        • Pavez M
        Clinical Chemistry in Women Treated with Levornogestrel Implants (NORPLANT®) or a TCu IUD.
        Contraception. 1983; 27: 281-288
        • Shaaban MM
        • Elwan SI
        • Abdallah SA
        • Darwish HA
        Effect of Subdermal Levonorgestrel Contraceptive Implants, Norplant®, on Serum Lipids.
        Contraception. 1984; 30: 413-419
        • Robertson DN
        Norgestrel-releasing Silastic Rods: Clinical Effects, Biochemical Effects and in vivo Release Rates.
        in: Advances in Human Fertility and Reproductive Endocrinology. Long acting Steroid Contraception. Vol 2. Raven Press, New York1983: 127-147
        • Shaaban MM
        • Elwant SI
        • El-Sharkawy MM
        • Farghay AS
        Effect of Subdermal Levonorgestrel Contraceptive Implants, Norplant®, on Liver Function.
        Contraception. 1984; 30: 407-412
        • Holma P
        • Robertson DN
        Cholesterol and HDL-cholesterol Values in Women during use of Subdermal Implants Releasing Levonorgestrel.
        Contraception. 1985; 32: 163-171